Timing of Off-Label Dosing of Direct Oral Anticoagulants in Three Large Health Systems.

BACKGROUND

While direct oral anticoagulants (DOACs) may be viewed as simpler to manage then warfarin, they present their own unique management challenges resulting in frequent off-label dosing. It is unknown to what extent off-label dosing occurs when a patient is started on a DOAC versus later in their treatment.

OBJECTIVES

We aimed to characterize when off-label DOAC dosing is occurring and to evaluate the effectiveness of prescribing oversight using a registry-based intervention.

METHODS

We evaluated data from the Michigan Anticoagulation Quality Improvement Initiative (MAQI2) registry, a retrospective quality improvement process using data abstractors, from 2018 - 2022 on the number of "alerts" that are generated in response to dosing deviating from evidence-based guidelines.

RESULTS

Among a sample of 1,261 to 1,563 annual DOAC-treated patients in the MAQI2 registry, off-label dosing was relatively common. Over the 5-year period from 2018 through 2022, there were 735 total dosing alerts. Alerts occurred more frequently during a follow-up than at the time of initial prescribing, 69.0% (507) versus 31.0% (228) respectively. After initial review by quality improvement abstractors, 18.2% of alerts (134) resulted in contact to the prescriber. When the prescriber was contacted, it led to an intervention 74.6% of the time. The most common intervention was a change in DOAC dosing.

CONCLUSIONS

This study demonstrates the benefit of DOAC prescribing oversight using a registry-based intervention to monitor for off-label dosing for the entirety of the time period a patient is prescribed DOAC as deviations in evidence-based prescribing occur frequently during the follow-up period.

Informations de copyright

Thieme. All rights reserved.

Déclaration de conflit d'intérêts

Geoffrey D. Barnes = Grant Funding - Boston Scientific; Consulting - Pfizer, Bristol-Myers Squibb, Janssen, Bayer, AstraZeneca, Sanofi, Anthos, Abbott Vascular, Boston Scientific; DSMB - Translational Sciences (Clinical Events Adjudication Committee); Board of Directors - Anticoagulation Forum Scott Kaatz = Consulting- AstraZeneca, Bristol-Myers Squibb, Boston Scientific, Gilead, Inari, Janssen, Pfizer, Phase Bio and Antos; Grant funding- Osmosis Research, Janssen, Bristol-Myers Squibb, Bayer and NIH; Board of Directors- Anticoagulation Forum, the PERT Consortium; Scientific Advisory Board for the National Blood Clot Alliance.